Anhui Wanbang Pharmaceutical TechnologyLtd Past Earnings Performance
Past criteria checks 1/6
Anhui Wanbang Pharmaceutical TechnologyLtd has been growing earnings at an average annual rate of 21.4%, while the Life Sciences industry saw earnings growing at 20.3% annually. Revenues have been growing at an average rate of 14.4% per year. Anhui Wanbang Pharmaceutical TechnologyLtd's return on equity is 7.3%, and it has net margins of 30%.
Key information
21.4%
Earnings growth rate
17.4%
EPS growth rate
| Life Sciences Industry Growth | 26.8% |
| Revenue growth rate | 14.4% |
| Return on equity | 7.3% |
| Net Margin | 30.0% |
| Last Earnings Update | 30 Jun 2024 |
Revenue & Expenses Breakdown
How Anhui Wanbang Pharmaceutical TechnologyLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 364 | 109 | 32 | 49 |
| 31 Mar 24 | 360 | 113 | 32 | 40 |
| 31 Dec 23 | 342 | 108 | 29 | 35 |
| 30 Sep 23 | 321 | 107 | 25 | 28 |
| 30 Jun 23 | 318 | 117 | 22 | 21 |
| 31 Mar 23 | 279 | 106 | 20 | 17 |
| 01 Jan 23 | 261 | 99 | 19 | 16 |
| 30 Jun 22 | 218 | 78 | 18 | 14 |
| 31 Mar 22 | 215 | 80 | 18 | 12 |
| 31 Dec 21 | 211 | 82 | 17 | 10 |
| 31 Dec 20 | 139 | 55 | 12 | 8 |
| 31 Dec 19 | 103 | 27 | 16 | 7 |
| 31 Dec 18 | 105 | 28 | 12 | 6 |
Quality Earnings: 301520 has a high level of non-cash earnings.
Growing Profit Margin: 301520's current net profit margins (30%) are lower than last year (36.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 301520's earnings have grown significantly by 21.4% per year over the past 5 years.
Accelerating Growth: 301520's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 301520 had negative earnings growth (-6.4%) over the past year, making it difficult to compare to the Life Sciences industry average (-6.4%).
Return on Equity
High ROE: 301520's Return on Equity (7.3%) is considered low.